 <h1>Menomune A / C / Y / W-135 Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>meningococcal polysaccharide vaccine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about meningococcal polysaccharide vaccine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Menomune A / C / Y / W-135.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to meningococcal polysaccharide vaccine: parenteral solution for im use</i></p><p>Side effects include:</p><p>MenACWY-D (Menactra<sup>®</sup>): Injection site reactions (e.g., pain, induration, erythema, swelling), headache, fatigue, malaise, arthralgia, diarrhea, anorexia, chills, fever, vomiting, rash. </p><p>MenACWY-CRM (Menveo<sup>®</sup>): Injection site reactions (tenderness, erythema), irritability, sleepiness, persistent crying, change in eating habits, vomiting, diarrhea in infants 2 through 23 months of age; injection site reactions (pain, erythema, induration), irritability, sleepiness, malaise, headache in children 2 through 10 years of age;  injection site pain, headache, myalgia, malaise, nausea in adults and adolescents. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to meningococcal polysaccharide vaccine: subcutaneous powder for injection</i></p><h3>General</h3><p>The most common adverse events were injection site pain, headache, irritability, and diarrhea.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain (48.1%), injection site redness (16%), injection site induration (11%), injection site tenderness</p><p><b>Common</b> (1% to 10%): Injection site swelling, injection site hematoma</p><p><b>Uncommon</b> (0.1% to 1%): Injection site reaction</p><p><b>Rare</b> (less than 0.1%): Severe local reactions</p><p><b>Postmarketing reports</b>: Extensive limb swelling at the injection site (frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (41.8%), drowsiness (11.2%)</p><p><b>Uncommon</b> (0.1% to 1%): Hypoesthesia, dizziness</p><p><b>Very rare</b> (less than 0.01%): Somnolence, neurological reactions</p><p><b>Postmarketing reports</b>: Vasovagal syncope, paresthesia, Guillain-Barre syndrome<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (32.3%), malaise (22.3%), fever</p><p><b>Common</b> (1% to 10%): Chills, febrile reactions (&gt;38C)</p><p><b>Postmarketing reports</b>: Asthenia, influenza-like symptoms<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Irritability (12.2%)</p><p><b>Uncommon</b> (0.1% to 1%): Insomnia, crying<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (16%)</p><p><b>Uncommon</b> (0.1% to 1%): Myalgia, pain in extremity</p><p><b>Postmarketing reports</b>: Musculoskeletal stiffness<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Appetite lost</p><p><b>Common</b> (1% to 10%): Anorexia</p><p><b>Postmarketing reports</b>: Decreased appetite<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (14%)</p><p><b>Common</b> (1% to 10%): Vomiting, nausea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus</p><p><b>Rare</b> (less than 0.1%): Urticaria, angioedema</p><p><b>Postmarketing reports</b>: Angioneurotic edema<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Local axillary lymphadenopathy<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity (such as rash, urticaria, pruritus, dyspnea, angioedema), allergic reactions (including anaphylactic and anaphylactoid reactions)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Upper respiratory tract illness</p><p><b>Rare</b> (less than 0.1%): Wheeze<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: IgA nephropathy<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Menomune (meningococcal polysaccharide vaccine)." Sanofi Pasteur, Toronto, IA. </p><h2>More about Menomune A / C / Y / W-135 (meningococcal polysaccharide vaccine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: bacterial vaccines</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Meningococcal Meningitis Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>